Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...3132333435363738394041...7475»
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Brolucizumab in pre-treated neovascular AMD with high treatment demand: a case series (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1049;    
    These results are comparable to the improvement seen in a similar situation after switch from Ranibizumab to Aflibercept reported several years ago. While phase 3 HAWK and HARRIER studies showed non-inferiority with longer treatment intervals compared to aflibercept, our cases indicate an improved short-term treatment response one months after switch to Brolucizumab eyes with high treatment-demand.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Interest of observational period before treat and extend treatment (OTI) in exudative AMD: two years results (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1048;    
    After a loading dose of 3 injections of Aflibercept or Ranibizumab each patient was examinated (ETDRS Fundus examination OCT) each month during 6 month... We conclude that observational period, between loading dose and treat and extend treatment, permit sparing eyes from unnecessary injections during the first year of treatment with preservation of the visual acuity and retinal dryness.Personalization of every new patient with exudative AMD could be beneficial for every actor of this medical care including the patient on the first plan.We think this simplified treatment layout compared to treat&extend permit to obtain equivalent results in ‘real life’ with comfort and superior patients adherence partly thanks to the objective OCT relapse after induction and their understanding of the injection schedule.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] One year real-world outcomes of anti-VEGF therapy in neovascular age related macular degeneration (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1047;    
    We conclude that observational period, between loading dose and treat and extend treatment, permit sparing eyes from unnecessary injections during the first year of treatment with preservation of the visual acuity and retinal dryness.Personalization of every new patient with exudative AMD could be beneficial for every actor of this medical care including the patient on the first plan.We think this simplified treatment layout compared to treat&extend permit to obtain equivalent results in ‘real life’ with comfort and superior patients adherence partly thanks to the objective OCT relapse after induction and their understanding of the injection schedule. •Ranibizumab Treat and extend gaves the highest gain in vision for nAMD patients•Ranibizumab Treat and extend and Aflibercept treat and extend has the similar number of injections in the first year•Ranibizumab Prn protocol has low number of injections but also lower vision gain.•Ranibizumab Treat and extend and Aflibercept treat and extend protocols show similar number of active patients, while prn protocol patients are more active•All the protocols were great in central retinal thickness reduction, which is greatest in the Aflibercept group.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Subretinal fluid in neovascular age-related macular degeneration: to treat or not to treat (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1046;    
    The authors report a case that suggests that the presence of isolated SRF can be relatively well tolerated, even in the acute/sub-acute stages of nAMD, with minimal negative effects on vision. The importance of protocols is undoubted, but an individualized approach still have its place, bearing in mind possible side effects of therapy, risk/benefit ratio and patient’s preferences and expectations.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Assessing the visual function in mCNV patients after anti-VEGF treatment (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1041;    
    Furthermore, exudative AMD was associated with increased aortic stiffness. Integral lifting in several aspects of visual function, included visual acuity, metamorphopsia, average macular sensitivity, macular integrity and the fixation ability, was observed in mCNV patients after ranibizumab treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Bilateral simultaneous intravitreal injections in a tertiary hospital (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1037;    
    Bilateral simultaneous intravitreal injections present a low rate of complications and are well-tolerated by patients. This will reduce the burden on the health care system and on the patients.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Anti-VEGF therapy of wet age-related macular degeneration: analysis of lost to follow-up patients in real clinical practice (preliminary report) (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1032;    
    The most common reasons for discontinuing anti-VEGF therapy (n = 83) were subjective dissatisfaction with IVT benefit, financial burden and general comorbidities, which were reported in 50 (60.2%), 27 (32.5%), 17 (20.5%) profiles respectively. Possible ways to increase patient's commitment to anti-VEGF therapy: early diagnosis and treatment initiation; selection of the most effective drugs and treatment regimens; individualization of treatment; organizational activities aimed at increasing the availability of specialized assistance.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Efficacy of switching a-vegf to aflibercept in wet amd treatment with ranibizumab resistance (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1031;    
    Switching A-VEGF therapy to IVI of aflibercept was accompanied by positive anatomical and functional dynamics and lengthening of the periods of relief of macular edema. To improve and prolong the anatomical and functional results of treating wet AMD, it is recommended that A-VEGF therapy be switched to aflibercept in resistance to ranibizumab after 15 IVI.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Preoperative anti-vascular endothelial growth factor injections for tractional retinal detachments: bevacizumab versus ranibizumab (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1013;    
    The value of observational insights from routine clinical practice in three different countries with a different health structure may lead to a better understanding of status quo and challenges in patient health care under real life settings and may therefore improve the quality and delivery of patient care. Preoperative bevacizumab(off-label) as an adjunct appears to be advantageous in reducing postoperative bleeding and aiding the complete removal of vitreous membranes in patients with macular involving diabetic tractional retinal detachments undergoing vitrectomy with membrane peeling, endolaser photocoagulation and silicone oil injection.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Scleral buckling surgery for active stage 4a and 4b retinopathy of prematurity (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_997;    
    Scleral buckling can be performed safely and effectively in 4a and 4b stage retinopathy of prematurity. This surgical technique may provide adequate relief of vitreoretinal traction with improved visual potential.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Antiangiogenic therapy combined with OCT-navigated laser in the treatment of macular edema secondary to branch retinal vein occlusion (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_907;    
    The first clinical results obtained by us indicate sufficient efficacy and safety of combined antiangiogenic therapy with the OCT navigated laser treatment of macular edema secondary to BRVO and require further study. Due to the topographically oriented technology approach, it became possible to clearly localize and precisely influence on the pathological areas, with minimal damage to the adjacent structures.Using this technique, it’s possible to reduce the number of injections to achieve a required clinical result.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Cost-consequence analysis of extended loading dose of anti-vegf treatment in diabetic macular edema patients (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_891;    
    The extension of anti-VEGF loading dose from 3 to 6 injections means that it would be necessary to invest €5,882.77 (8 injections), €10,091.03 (14 injections) and €10,198.59 (30 injections) per additional patient (3-month non-responder and 6-month responder) responding to aflibercept, ranibizumab and bevacizumab, respectively. For the total of patients treated, on average €7,927.02 per additional responder patient would be needed.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Drug utilization in patients treated with anti-VEGFs for diabetic macular edema (DME) in the UK (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_884;    
    Our data shown an average number of injections during the first year of treatment that was numerically higher (7.7) compared to those reported in the POLARIS (7.4) and Moorfields Eye Hospital (6.7).Overall >59%, >27% of treated eyes had treatment free intervals ≥q12-, ≥q16-weeks during the first and second years after treatment initiation. However, in many of the cases extension by >12 weeks occurred only once (during the entire two-year period).Our results highlight the need for therapeutic solutions that enable sustainable extended injection intervals while controlling anatomical parameters and improving and maintaining long-term vision.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Under pressure – a cohort analysis of sustained-elevation intraocular pressure in long-term VEGF inhibitor therapy (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_871;    
    Regardless of the indication, regular intravitreal anti-VEGF injections (?of Bevacizumab, Ranibizumab or Aflibercept) do not appear to be associated with an increased risk of SEIOP post-injection. A previous history of glaucoma is the greatest risk factor for SEIOP in these patients.The intraocular pressure of patients with a history of glaucoma should be monitored carefully, including when being treated with intravitreal Anti-VEGFs.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] 24-month outcomes of intravitreal aflibercept in the United Kingdom for diabetic macular oedema (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_867;    
    Fourty-nine (62.8%) and five (6.4%) eyes were previously treated with intravitreal ranibizumab and intravitreal dexamethasone implants respectively and had stopped responding to treatment... Intravitreal aflibercept is a safe treatment for DMO, significantly improving vision in a real-world cohort with significant ocular co-morbidities that had responded poorly to other treatments.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Should we use intravitreal dexamethzone implant as an adjuvan therapy or switch therapy in refractory diabetic macula edema (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_833;    
    Purpose: To compare the outcomes of intravitreal dexamethasone implant used as an adjuvant therapy or a switching therapy in diabetic macula edema in the event of anatomical poor response after 3 consecutive monthly ranibizumab. In a real-world setting, eyes with DME considered refractory to ranibizumab therapy after three monthly injections which were switched to IDI implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with ranibizumab therapy after IDI as an adjuvan therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Central multifocal choroiditis: an evaluation of different treatment options in pregnancy. (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_792;    
    Overall, no major complications were observed in patients treated with immunosuppressive medication or intravitreal anti-VEGF injections. Although more relapses occurred in pregnancies without immunosuppressive treatment, we emphasize no definite conclusions can be drawn based on this small retrospective study.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Involution of retinopathy of prematurity and neurodevelopmental outcomes after Intravitreal Lucentis (ranibizumab) treatment (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_704;    
    Purpose: This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (ROP) and retinal vascularization to zone III after intravitreal bevacizumab (IVB) treatment and its possible impacts on postnatal growth and neurodevelopment Setting: KASER ALINE FACULTY OF MEDICIN CAIRO UNEVISTY CAIRO EGYPT Premature infants with birth weight ‰¤1500 g, born between 2008 to 2014 and diagnosed with ROP were enrolled. : Long-term follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] Ranibizumab non-response in pachychoroid neovasculopathy: effects of switching to aflibercept (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_644;    
    : Long-term follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age In cases of PNV not responding to intravitreal ranibizumab, switching treatment to aflibercept seems to represent an effective treatment approach to resolve persistent fluid and achieve a dry macula.